Mizuho Maintains Outperform on Kymera Therapeutics, Raises Price Target to $140

Benzinga Newsdesk www.benzinga.com Positive 93.1%

Neg 0% Neu 0% Pos 93.1%

Mizuho analyst Joseph Catanzaro maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target from $120 to $140.